

Elucidating the chlamydial growth
characteristics, infection factors, and
host responses to persistent chlamydial
infection in women

MARK JAMES THOMAS

Bachelor of Biomedical Science (First-Class Honours), QUT

School of Life Sciences

A thesis submitted to the University of Technology Sydney School of Life Sciences,
in fulfilment of the degree of Doctor of Philosophy

Supervised by:

Associate Professor Wilhelmina Huston

Associate Professor Garry Myers

Professor Peter Timms

2019

Certificate of original authorship

I, Mark Thomas, declare that this thesis is submitted in fulfilment of the requirements for the award of Doctor of Philosophy, in the School of Life Sciences at the University of Technology Sydney. This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis. This document has not been submitted for qualifications at any other academic institution. This research is supported by the Australian Government Research Training Program.

Production Note:

Signature removed prior to publication.

Signature of Mark Thomas

25/11/2019

Date submitted

List of key words

Chlamydia trachomatis, treatment failure, clinical isolates, infertility, microbiome, persistence, host immune response, gene expression, azithromycin.

List of figures

- Figure 1.1.* Overview of the chlamydial developmental cycle.
- Figure 1.2.* The production of IFN- γ by human and murine host cells is a key defence against intracellular pathogens such as *C. trachomatis*.
- Figure 1.3.* The relationship between *C. trachomatis*, IFN- γ and indole-producing bacteria.
- Figure 1.4.* The four major models proposed by Menon and colleagues as mechanisms of chlamydial infertility in women.
- Figure 1.5.* The innate and adaptive components of the host immune defence against chlamydial infection.
- Figure 1.6* The role of the vaginal microbiota in gynecological health and dysbiosis.
- Figure 1.7.* An overview of the relationship between diverse microbial populations and the immunopathology associated with intracellular pathogens such as *C. trachomatis* and *Mycoplasma genitalium*.
- Figure 3.1.* The relative proportion of the 25 most abundant taxonomic assignments.
- Figure 3.2.* Community state types dominated by *Lactobacillus* were present in the majority of specimens.
- Figure 3.3.* Relative abundance (%) of sequences per sample mapped to *Ureaplasma* species.
- Figure 3.4.* PCR amplification of the multiple banded antigen (*mba*) in samples with sequences corresponding to *Ureaplasma* spp.

- Figure 3.5.* Alpha-diversity comparisons of the microbiota grouped by case-control status.
- Figure 3.6.* Alpha-diversity comparisons of the microbiota grouped by contraceptive use.
- Figure 3.7.* Endometrial expression of six selected genes with known implications for endometrial pathology or function.
- Figure 3.8.* Expression of selected endometrial genes grouped by participant factors.
- Figure 4.1.* The percent infectivity of four clinical isolates and D/UW-3/Cx in various cell lines.
- Figure 4.2.* The growth and infectivity of *C. trachomatis* clinical isolates and a type strain in different mammalian cell lines.
- Figure 4.3.* Viability of clinical isolates and the type strain in conditions of iron deprivation.
- Figure 4.4.* Viability of five clinical isolates and the type strain following treatment with bipyridal and azithromycin.
- Figure 4.5.* Morphological characterisation of a clinical isolate and type strain of *C. trachomatis* after treatment with bipyridal.
- Figure 4.6.* Viability of the chlamydial isolates and type strain after treatment with penicillin.
- Figure 4.7.* Morphological appearance of clinical isolates and the type strain of *C. trachomatis* during penicillin persistence.
- Figure 4.8.* Viability of clinical isolates and D/UW-3/Cx after treatment with azithromycin during penicillin persistence.
- Figure 5.1.* Criteria and details used in the recruitment of participants in the ACTS study, and those used for subselection in this case-control study.

Figure 5.2. Endocervical gene expression in women who were treated for chlamydia with azithromycin.

Figure 5.3. RT-qPCR analysis of chlamydial gene expression in women who received 1 g azithromycin as treatment for *C. trachomatis* urogenital tract infections.

Figure 6.1. Flowchart describing the factors being investigated and aims of the project.

List of tables

- Table 2.1.* Details and testing of swab specimens collected from ACTS participants.
- Table 2.2.* Details of the PCR used to perform ad hoc testing of cell lines for contamination with *Mycoplasma* spp.
- Table 3.1* Comparison and analysis of fertility, epidemiological, and gynecological factors, grouping by case-control status.
- Table 3.2.* Number and details of samples extracted and analysed.
- Table 3.3.* Associations between the presence of microbial taxa and the collected participant data.
- Table 3.4.* Number of filtered reads mapped to *Ureaplasma*.
- Table 4.1.* Details of the mammalian cell lines used in this study.
- Table 4.2.* Identification and details of the *C. trachomatis* clinical isolates and strains used in this study.
- Table 4.3.* Viability of the *C. trachomatis* clinical isolates and type strain at 44 h PI.
- Table 4.4.* Viability of the *C. trachomatis* clinical isolates and type strain at 54 h PI.
- Table 5.1.* Human genes selected for expression analysis by RT-qPCR.
- Table 5.2.* Chlamydial genes selected for expression analysis by RT-qPCR.
- Table 5.3.* Participant demographic data comparing the case and control groups.
- Table 5.4.* Significance of observed differences in expression of human genes in the control and case groups.

Table 5.5. Gene expression data divided into the three original groups to show the mean, SEM and count (N).

List of appendices

- Appendix I.* Supplementary table showing the read counts from 16S rRNA gene amplicon sequencing before filtering, after filtering and after taxonomic assignment.
- Appendix II.* The relative proportions of all taxonomic assignments in the samples grouped on the basis of the anatomical sites (vagina, cervix or endometrium).
- Appendix III.* Reaction conditions and oligonucleotide sequences used in RT-qPCR analysis of samples from the endometrial tissue specimens of women in the case-control fertility study.
- Appendix IV.* Oligonucleotide sequences used during host gene expression analysis by RT-qPCR.
- Appendix V.* Oligonucleotide sequences used during chlamydial gene expression analysis by RT-qPCR.
- Appendix VI.* RT-qPCR plots of the ten human genes of interest after subdivision of the groups.
- Appendix VII.* RT-qPCR plots of the five chlamydial genes of interest tested compared after subdivision of the case group.

List of abbreviations

$\% v v^{-1}$	Percentage volume of total volume
$\% w v^{-1}$	Percentage weight of total volume
16S rRNA	16S ribosomal ribonucleic acid
AB	Aberrant body
ACTS	Australian Chlamydia Treatment Study
bp	Base pair
Bpdl	Bipyridal
BSA	Bovine serum albumin
BSC	Biosafety cabinet
cDNA	Complementary deoxyribonucleic acid
CST	Community state type
Ct	Chlamydia trachomatis
CtD	Chlamydia trachomatis D serovar
CXCL9	Chemokine (CXC motif) ligand 9
DAPI	4',6-diamidino-2-phenylindole
DC	Dendritic cell
DMEM	Dulbecco's Modified Eagle Medium
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DNase	Deoxyribonuclease
DPBS	Dulbecco's phosphate-buffered saline

dsDNA	Double-stranded deoxyribonucleic acid
EB	Elementary body
euo	Early upstream open reading frame
FCS	Fetal calf serum
FITC	Fluorescein isothiocyanate
FRT	Female reproductive tract
FTH1	Ferritin heavy chain 1
g	Gravity of Earth
GAG	Glycosaminoglycans
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
gDNA	Genomic deoxyribonucleic acid
GFP	Green fluorescent protein
GLUT1	Glucose transporter-1
h	Hours
h PI	Hours post infection
H+L	Heavy and light chains
HctA	Histone Hc1-like <i>Chlamydia trachomatis</i> protein
HctB	Histone Hc2-like <i>Chlamydia trachomatis</i> protein
HIV	Human immunodeficiency virus
HREC	Human Research Ethical Committees
Hsp	Heat shock protein
Hsp60	60-kilodalton heat shock protein
Hsp70	70-kilodalton heat shock protein
HSV	Herpes simplex virus

htrA	High temperature requirement A
HIF-1 α	Hypoxia inducible factor-1 α
IB	Intermediate body
IDO1	Indoleamine 2,3-dioxygenase
IF	Immunofluorescence (microscopy)
IFNG	Interferon gamma
IFU	Inclusion forming unit
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IgM	Immunoglobulin M
IL1A	Interleukin-1- α
IL6	Interleukin 6
IL8	Interleukin 8
IL10	Interleukin 10
inc	Inclusion (protein)
IRF1	Interferon regulatory factor 1
kDa	Kilodalton
kU	Kilo unit
LPS	Lipopolysaccharide
maU ml ⁻¹	Milli-Anson Units per milliliter
MCC	Minimum chlamydical concentration
MEC	2-C-methylerythritol 2,4-cyclodiphosphate
MEP	Melavonate methylerythritol 4-phosphate
MIC	Minimum inhibitory concentration

MOI	Multiplicity of infection
MOMP	Major outer membrane protein
NAAT	Nucleic acid amplification testing
NK	Natural killer (cell)
NTC	No-template control
OM	Outer membrane
omcB	Outer membrane protein B
omp	Outer membrane protein
ompA	Outer membrane protein A
PAMP	Pathogen-associated molecular pattern
PBMC	Peripheral blood mononuclear cell
PBP	Penicillin-binding protein
PCR	Polymerase chain reaction
PID	Pelvic inflammatory disease
Pmp	Polymorphic membrane protein
Pmp21	Polymorphic membrane protein 21
qPCR	Quantitative polymerase chain reaction
QUT	Queensland University of Technology
RB	Reticulate body
RNA	Ribonucleic acid
RNase	Ribonuclease
RT-qPCR	Reverse transcription quantitative polymerase chain reaction
s	Seconds

SNP	Single nucleotide polymorphism
SPG	Sucrose phosphate glutamate
SRA	Sequence read archive
STI	Sexually transmitted infection
SYBR	Synergy Brands
T3SS	Type three secretion system
TARP	Translocated actin-recruiting protein
TBE	2-amino-2-hydroxymethyl-propane-1,3-diol, boric acid ethylenediaminetetraacetic acid
TFI	Tubal factor infertility
TLR	Toll-like receptor
TNC	Tenascin-C
TNFA	Tumour necrosis factor alpha
Tris	2-amino-2-hydroxymethyl-propane-1,3-diol, boric acid ethylenediaminetetraacetic acid
TRITC	Tetramethylrhodamine
trpBA	Tryptophan synthase B/A
U	Unit
USC	University of the Sunshine Coast
UTS	University of Technology Sydney

Abstract

Chlamydia trachomatis is an obligate intracellular parasite and the leading cause of sexually transmitted bacterial infections in the human urogenital tract. Clinical manifestations of chlamydial infection include urethritis, cervicitis, pelvic inflammatory disease and tubal factor infertility. These pathological conditions are caused by the immune response to both acute and chronic chlamydial infections. Evidence suggests a high proportion of infections remain subclinical until spontaneous resolution or the commencement of symptoms leads to a diagnosis. Therefore, a substantial proportion of the morbidity and burden associated with chlamydia can likely be attributed to unresolved and untreated infections. While treatment with azithromycin is highly effective, treatment failure does occur. The mechanisms of treatment failure and its effects on fertility are poorly understood. Unlike other bacterial pathogens, *C. trachomatis* lacks stable genotypic resistance to macrolides. Another key difference between *Chlamydia* and many other bacteria is the constant interaction with its host cell. Thus, it was hypothesised that the unique intracellular niche and developmental cycle of *C. trachomatis* are important microbial factors which could affect treatment efficacy. To test this, several host and chlamydial factors were investigated. 16S rRNA gene amplicon sequencing of vaginal and cervical swabs and endometrial biopsies from participants of a case-control fertility study revealed that similarities in the microbial populations of the vagina and cervix were not predictive of those in the endometrium. While there was no association

between microbial community compositions and fertility status identified, *Ureaplasma* spp. were overrepresented amongst infertile women. The endometrial expression of several genes involved in immunity and reproductive function showed no association with microbial community composition, however, the gene which encodes tenascin-C was over-expressed in women who had a self-reported history of miscarriage. Comparisons of clinical isolates from women treated for chlamydial infections showed no significant differences in developmental or stress phenotypes but suggested that the subtle differences observed using *in vitro* models may not truly reflect the complexity of *in vivo* infectious processes. Finally, analysis of host and chlamydial gene expression before and after antibiotic treatment showed no association with outcome but yielded valuable information about the host and pathogen during the period following treatment. In particular, chlamydial gene expression was upregulated after they had survived treatment with azithromycin. This project has contributed towards current knowledge and increases the field's understanding of the host and chlamydial factors involved in treatment failure and infertility. Additionally, it provides insight for future investigations of these important and complex interactions between humans and the bacteria which have evolved alongside us.

Acknowledgements

Over the course of my life, I have been incredibly fortunate enough to have access to education. I am forever grateful for these valuable opportunities, and they have bestowed upon me an unwavering belief in the importance of continued learning. For this, I would like to thank the Queensland University of Technology, University of Technology Sydney, and the Australian Government. My time as a PhD student has likely been the most difficult period in my 29 years of life. It has been a task that I truly believe would have been impossible for me to persevere with and navigate through, without the incredible support, personal and professional guidance, and sage teachings of Willa – my supervisor. For these qualities and everything else you have provided me with over the years, I am forever grateful. Of course, I would like to extend my sincerest thanks to my family, especially my mother, for being there to help me through the ups and downs that I encountered both in Brisbane and in Sydney. The friends I have made along the way have also been of great assistance, and I wish to personally thank James Marsh, Regan Hayward, and Rami Mazraani for being great people. Finally, I would like to thank my amazing partner Megan for her continued support and reassurance, and the love and friendship she has relentlessly bestowed upon me while I worked on my project – and in general.

Thesis statement

I am submitting my work titled “Elucidating the chlamydial growth characteristics, infection factors, and host responses to persistent chlamydial infection in women” as a conventional thesis, in accordance with the University of Technology Sydney (UTS) Graduate Research School (GRS) Research Candidature Management, Thesis Preparation and Submission Procedures.

Author contribution statements

Chapter 3

Wee, B. A.*, **Thomas, M.***, Sweeney, E. L., Frentiu, F. D., Samios, M., Ravel, J., . . .

Huston, W. M. (2018). A retrospective pilot study to determine whether the reproductive tract microbiota differs between women with a history of infertility and fertile women. *Aust N Z J Obstet Gynaecol*, 58(3), 341-348. doi:10.1111/ajo.12754

*these authors contributed equally to the study.

BAW conducted all bioinformatics analysis and contributed to the drafting of the manuscript. MT conducted laboratory components, RT-qPCR and related statistical analysis and contributed to the drafting of the manuscript. ELS contributed to the design and interpretation of RT-qPCR and contributed to the drafting of the manuscript. FDF contributed to the design and interpretation of RT-qPCR and contributed to the drafting of the manuscript. MS contributed to participant recruitment, questionnaire design and data collection, and contributed to the drafting of the manuscript. JR contributed to bioinformatics design and analysis of the microbiota data and contributed to the drafting of the manuscript. PG contributed R scripts, bioinformatics design and analysis of the microbiota data and contributed to the drafting of the manuscript. GM contributed to bioinformatics design and analysis of the microbiota data and contributed to the drafting of the manuscript. PT contributed to design and interpretation of RT-qPCR and contributed to the drafting of the manuscript. JAA conceived the concept of the study, conducted clinical

xx

recruitment, epidemiological and questionnaire analysis and contributed to the drafting of the manuscript. WMH developed the case-control study design, contributed to statistical analysis and interpretation and contributed to the drafting of the manuscript.

Chapter 4

Amba Lawrence (QUT) conducted the initial isolation of clinical isolates from ACTS swabs and the growth and infectivity assays. Sam Kroon (UTS) performed the iron deprivation chlamydial persistence assays and analysed the results. Mark Thomas (UTS) was responsible for assisting with aspects of experimental design, expansion of the clinical isolates for use in persistence models, penicillin persistence growth assays, the penicillin-azithromycin recovery assays, all confocal imaging shown, interpretation and analysis of data, construction and standardization of figures, and drafting of the paper with the intent of future publication. Wilhelmina Huston (UTS) developed major experimental design components, drafting of the paper, analysis and interpretation of findings. Peter Timms assisted with drafting and aspects of the experimental design. Jane Hocking conceived ACTS and provided access to the clinical isolates of *C. trachomatis* used in this study.

Chapter 5

Mark Thomas (MT) was involved in experimental design, analysis and interpretation of the results, drafting of the manuscript for future publication, and all of the technical components and procedures described. Wilhelmina Huston was responsible for the study conception, analysis and interpretation of the results, and drafting. Peter

Timms assisted with drafting of the manuscript and some components of the experimental design. Jane Hocking conceived ACTS and provided feedback on drafted versions of the paper.

Table of Contents

<i>Certificate of original authorship</i>	<i>iii</i>
<i>List of key words</i>	<i>iv</i>
<i>List of figures</i>	<i>v</i>
<i>List of tables</i>	<i>viii</i>
<i>List of appendices</i>	<i>x</i>
<i>List of abbreviations</i>	<i>xi</i>
<i>Abstract</i>	<i>xvi</i>
<i>Acknowledgements</i>	<i>xviii</i>
<i>Thesis statement</i>	<i>xix</i>
<i>Author contribution statements</i>	<i>xx</i>
<i>Table of Contents</i>	<i>xxiii</i>
CHAPTER 1: LITERATURE REVIEW	30
Foreword	31
<i>Part 1: Chlamydia trachomatis</i>	33
Overview	33
Chlamydial developmental biology.....	33
Chlamydial persistence.....	38

The host immune system and <i>C. trachomatis</i>	44
Treatment of <i>C. trachomatis</i> infections of the urogenital tract	52
<i>Part 2: The reproductive tract microbiome of women</i>	55
The role of the female reproductive tract microbiome	55
Pathologies attributed to shifts in microbial populations.....	57
The human vaginal microbiome and <i>C. trachomatis</i>	58
<i>Part 3: Scope and purpose of the project</i>	60
Research Problem	60
Overview of the research project.....	60
CHAPTER 2: GENERAL METHODS AND MATERIALS	62
<i>Part 1. Methods</i>	63
General research methodology	63
Mammalian cell culture	65
Bacterial culture	72
Microscopy	75
Nucleic acid analysis	77
<i>Part 2. Materials</i>	80
Buffers, solutions and chemicals	80
Mammalian cell lines and <i>C. trachomatis</i> isolates	81
Antibodies.....	82
Proprietary kits.....	83
Software.....	83

Equipment and machines	84
CHAPTER 3: A CASE-CONTROL STUDY OF THE VAGINAL, CERVICAL, AND ENDOMETRIAL MICROBIOTA IN WOMEN WHO HAVE A HISTORY OF INFERTILITY USING 16S rRNA GENE AMPLICON SEQUENCING	86
<i>Chapter notes</i>	87
<i>Abstract</i>	88
<i>Introduction</i>	90
<i>Methods</i>	93
Study design	93
Ethics approval and consent to participate	94
Specimen collection	94
Sample processing.....	95
16S rRNA gene amplification and sequencing.....	97
Sequence analysis	98
Statistical analysis.....	99
<i>Ureaplasma</i> detection and quantification	99
Total RNA extraction from endometrial tissue	100
Endometrial gene expression analysis	100
<i>Results</i>	102
Case-control groups were comparable for gynecological factors, although age was significantly different	102

The microbiota profile was consistent in the cervical and vaginal samples from each individual, but the endometrium often had a distinct composition of microbiota 105

Ureaplasma spp. were more frequently identified in the vaginal and cervical microbiota of women with a history of infertility (cases)..... 112

Alpha diversity was not significantly different in infertile women compared to fertile women, but was significantly higher in the endometrium of women using LNG-IUS 116

Endometrial gene expression most significantly correlated with a history of miscarriage and contraceptive use, rather than a history of infertility or microbiota composition 119

Discussion 122

Conclusion..... 128

CHAPTER 4: CLINICAL ISOLATES SHOW SUBTLE DIFFERENCES IN PERSISTENCE PHENOTYPES AND GROWTH *IN VITRO*..... 129

Chapter notes 130

Abstract..... 131

Introduction 133

Materials and methods 136

Cell culture and cultivation of *C. trachomatis* 136

Infectivity and determination of viable progeny 138

Penicillin persistence model 139

Assessing azithromycin susceptibility during persistence	140
Iron deprivation culture model	141
<i>Results</i>	143
Differences between the infectivity and growth of clinical isolates are more profound than the differences caused by the cell line	143
Clinical isolates show similar susceptibilities to conditions of iron deprivation at lower doses than D/UW-3/Cx.....	147
Treatment with azithromycin during iron deprivation-induced persistence decreases the number of recoverable infectious progeny among clinical isolates.....	149
Clinical isolates entered persistence at lower doses of penicillin compared to the type strain D/UW-3/Cx	152
Clinical isolates treated with azithromycin during penicillin persistence showed a dose-dependent decrease in recoverable infectious progeny	155
<i>Discussion</i>	157

**CHAPTER 5: ANALYSIS OF HOST AND CHLAMYDIAL GENE
EXPRESSION IN WOMEN TREATED FOR *C. trachomatis* INFECTIONS OF
THE UROGENITAL TRACT** 161

<i>Chapter notes</i>	162
<i>Abstract</i>	163
<i>Introduction</i>	165
<i>Methods</i>	171

A nested case-control study to investigate the host and pathogen expression profiles in women receiving treatment for *C. trachomatis* urogenital tract infections 171

Samples used in the present study 172

RNA extraction and complementary DNA synthesis 174

Measuring relative human gene expression levels in cDNA samples 174

Measuring relative chlamydial gene expression levels in cDNA samples 177

Data analysis and statistical testing..... 178

Results 180

Statistical comparison of the case and control groups“ demographic data showed both groups were similar with no significant differences in the variables used in the matching of participants 180

The expression of host genes involved in localised and host-cell mediated responses to intracellular pathogens is significantly lower than on day one if treatment fails to resolve infection..... 182

Chlamydial gene expression analysis suggests that infections present after treatment were a combination of phenotypically stressed and actively replicating sub-clusters..... 186

Discussion 191

CHAPTER 6: GENERAL DISCUSSION AND FUTURE DIRECTIONS 199

Scope and purpose of this research project 200

Aim 1 203

Aim 2.....	209
Aim 3.....	214
Conclusion.....	216
Future directions	217
APPENDICES	221
<i>Appendix I</i>	222
<i>Appendix II</i>	228
<i>Appendix III</i>	229
<i>Appendix IV</i>	230
<i>Appendix V</i>	231
<i>Appendix VI</i>	232
<i>Appendix VII</i>	234
References	237